2425 55th Street, Suite 210 Boulder, CO 80301 303-420-4420

News-Home

Bolder BioTechnology Announces Publication of Data Demonstrating Utility of the Company’s Long-Acting IL-11 Analog to Prevent Renal Ischemia Reperfusion Injury

Boulder, Colorado¬†- August 28, 2012 - Bolder BioTechnology, Inc. announced today publication of preclinical research demonstrating utility of interleukin-11 (IL-11) and the company's long-acting IL-11 analog to prevent kidney damage from ischemia reperfusion injury in mice. This work may lead to new therapeutic approaches to prevent acute kidney injury and ischemia reperfusion injury to multiple…
Read more